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ABSTRACT  27 
 28 
The virulence markers and the antimicrobial resistance profile of 78 Escherichia coli 29 
isolates causing obstetric infections accompanied or not by sepsis were studied. 30 
Adhesion-related virulence factors were the most prevalent. Low rates of resistance to 31 
the antimicrobial agents used as first line therapy suggest their correct implementation 32 
in stewardship guidelines. 33 
34 
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Escherichia coli are the enteric Gram-negative bacilli most frequently found in the 35 
genital tract of women. Despite their commensal role, these microorganisms can 36 
become pathogenic colonizing new environments. Extraintestinal E. coli is the second 37 
most prevalent etiologic agent causing obstetric infections (1). E. coli possesses several 38 
virulence factor genes (VFG) that enhance vaginal and/or endocervical colonization in 39 
pregnant women. This colonization can lead to different infections in obstetric patients, 40 
such as intra-amniotic infection (IAI) or endometrial and urinary tract infection (UTI), 41 
sometimes accompanied by sepsis. In addition, these microorganisms can cause 42 
neonatal infections leading to mother and fetal morbidity and mortality (2, 3). It has 43 
been estimated that 15% of pregnant and 12% of non-pregnant women in our hospital 44 
present E. coli in the genital tract (4).  45 
The treatment of choice in maternal sepsis includes the administration of different 46 
antimicrobial agents depending on the focus, being limited by the low number of the 47 
antimicrobial agents considered to be safe to the fetus (5). In our hospital, the treatment 48 
of choice in patients with IAI consists of ceftriaxone; ampicillin/gentamicin or 49 
ampicillin/cefoxitin while the treatment of endometritis involves the use of  50 
ampicillin/gentamicin/metronidazol.  51 
In general lines, among the virulence factors involved in UTI, it is well-known that 52 
adhesins, fimbriaes and toxins are the most important as they allow the bacteria to 53 
adhere to the uroepithelium and cause tissue damage. However, further knowledge is 54 
necessary regarding its prevalence and the role of other families of virulence factors in 55 
the specific field of obstetric infections derived from UTIs.  56 
57 
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For this purpose, 78 E. coli isolates from pregnant women attending the Hospital Clinic 58 
of Barcelona from 1987 to 2010 were included in the study: 56 were isolated from the 59 
blood of patients with sepsis from a genital or urinary focus and 22 isolated from 60 
amniotic fluid or placenta of patients with non-bacteremic IAI.   61 
Resistance profiles were determined using the disk diffusion method. The antimicrobial 62 
agents tested are listed in Table 1 and include the first therapeutic options to treat UTI 63 
and genital infections. The results were interpreted following CLSI guidelines (6) and 64 
the E. coli ATCC25922 strain was used as the control.  65 
The VFG profile of the isolates was analyzed by PCR using gene-specific primers for 66 
the virulence genes encoding for the adhesins, toxins and invasins most prevalent in the 67 
uropathogenic E. coli (UPEC) isolates described, from which the isolates causing the 68 
obstetric infections studied potentially come from. Isolates were also screened for 5 69 
specific virulence markers for extraintestinal pathogenic E. coli (ExPEC) or non-ExPEC 70 
classification (7).The  PCR conditions used were 94ºC for 4 minutes, followed by 30 71 
cycles of 94ºC for 30 seconds, with the corresponding annealing temperature (55-63ºC) 72 
for 30 seconds, 72ºC for 2 minutes and a final elongation cycle of 72ºC for 5 minutes. 73 
Samples were run in 1.5% agarose gels and stained with SYBR Safe DNA Gel Stain 74 
(Invitrogen, Spain). The E. coli phylogenetic group was determined using the 3 locus 75 
PCR-based method described previously (8). In order to determine if any isolate 76 
belonged to ST131, serotype O25b was identified in the collection according to the 77 
methodology proposed by Clermont et al. (9), and the multi-locus sequence typing 78 
(MLST) methodology was carried out with these isolates using the University of 79 
Warwick database for assigning sequence types (ST). 80 
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Statistical analysis was performed using Stata version 13.1 (Stata Corp. TX, USA). P-81 
values less than 0.05 were accepted as significant and statistical correction for multiple 82 
comparisons was applied. 83 
 84 
Twenty isolates (26%) were resistant to three or more antimicrobial classes, presenting 85 
a multi-drug resistant (MDR) phenotype. Sixty-three percent of all the isolates were 86 
resistant to ampicillin whereas only 13% were resistant to amoxicillin-clavulanic acid. 87 
Most of the isolates were susceptible to 2nd and 3rd generation cephalosporins, 88 
imipenem, aminoglycosides, ciprofloxacin and chloramphenicol, with higher rates of 89 
resistance for tetracycline, trimethoprim/sulphametoxazole, cefazolin, and nalidixic 90 
acid. Isolates causing sepsis had a lower prevalence of resistance to nalidixic acid, with 91 
a higher percentage of resistance being observed with cephazolin (Table 1).  92 
The most prevalent VFG found among the isolates were adhesion-related, with 93 
percentages between 56 and 86%. The isolates harboring the greatest number of  VFG 94 
were those causing sepsis, with a significantly higher percentages of hlyA, cnf1, papA, 95 
iha, fyuA or papGII, all contained in pathogenicity islands. Regarding virulence factors 96 
related to iron recruitment, the iutA gene was found significantly more frequently in IAI 97 
causing isolates (p=0.0001) whereas the iroN gene was the most common in sepsis 98 
producing isolates (p=0.0284). Multivariate analysis of VFG showed the presence of the 99 
fimA, iucC, iroN, iutA, iha and hra genes as independent predictors for sepsis-causing 100 
isolates (Table 2). Seventy-eight percent of the isolates (with no significant differences 101 
between the sepsis and non sepsis-causing isolates) were classified as ExPEC according 102 
to the virulence markers harbored, and only two of these isolates belonged to ST131. 103 
 104 
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Analysis of the presence of each VFG among the resistance profiles of the isolates to 105 
each of the antimicrobial agents tested was carried out showing that susceptible isolates 106 
had a higher carriage of VFG. 107 
The phenotypic results of antimicrobial resistance observed in the present study 108 
indicated high levels of ampicillin-resistant isolates among the collection, in accordance 109 
with those found in E. coli isolates causing neonatal sepsis and in extraintestinal E. coli 110 
in general (10). On the other hand, the low rates of resistance to amoxicillin/clavulanic 111 
acid and second and third generation cephalosporins observed in the present study are in 112 
contrast with the increasing appearance of ESBLs-carrying strains in the last years 113 
causing infections from other sources, suggesting that the implementation of these 114 
antimicrobial agents as first line therapy in these types of infections is correct (11). 115 
Nonetheless, the treatment administered should still be chosen depending on the rates of 116 
resistance to gentamicin and cephalosporins in E. coli causing obstetric infections in 117 
each hospital, as well as the prophylaxis or previous treatment with these antimicrobial 118 
agents which have led to the development of resistant bacteria.  119 
Regarding the VFG present in E. coli involved in the obstetric infections studied, it was 120 
found that adhesins and fimbriae may play an important role in the development of 121 
these infections, allowing the bacteria to colonize different environments. The higher 122 
prevalence of hlyA and cnf1 among the isolates causing sepsis could be related to the 123 
tissue damage involved in these infections. Concerning the iron recruitment systems, the 124 
yersiniabactin receptor encoded by fyuA and the siderophores receptors Iha and IroN 125 
encoding genes were also more prevalent among the isolates causing sepsis, due to the 126 
need for UPEC to capture iron from the host within the hostile environment of urine. 127 
These virulence factors have been largely described as characteristic in UPEC (12). On 128 
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the other hand, iutA was more frequently found in isolates causing IAI, elucidating a 129 
high adaptation capacity according to the particular microenvironmnent colonized.  130 
A specific relationship was found between TE-resistant isolates and the lower presence 131 
of several VFG included in PAIs, similar to the previously described relationship 132 
between acquisition of quinolone resistance and the loss of VFG (13). 133 
In conclusion, to date, E. coli isolates causing obstetric infections present similar rates 134 
of antimicrobial resistance to those described for extraintestinal E. coli infections, 135 
except for a lower prevalence of resistance to third generation cephalosporins, thereby 136 
not carrying ESBL. These results demonstrate that the administration of antimicrobials 137 
in our hospital is correct. However, it is important to establish surveillance networks 138 
specific for these kinds of infections in order to adapt stewardship programs when 139 
appropriate. 140 
141 
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TABLE 1. Percentage of resistance to antimicrobial agents in E. coli isolates according 199 











Ampicillin  13 (59%) 36 (64%) 49 (63%) 0.6692 1 
Amoxicillin 
/clavulanic acid 
 3 (14%) 7 (12%) 10 (13%) 1.0000 2 
Cefazolin  3 (14%) 14 (25%) 17 (22%) 0.3680 2 
Cefuroxime  1 (5%) 2 (4%) 3 (4%) 1.0000 2 
Cefoxitin  0 (0%) 1 (2%) 1 (1%) 1.0000 2 
Cefotaxime  1 (5%) 1 (2%) 2 (3%) 0.4872 2 
Ceftazidime  0 (0%) 0 (0%) 0 (0%) - 
Imipenem  0 (0%) 0 (0%) 0 (0%) - 
Piperacillin 
/tazobactam 
 0 (0%) 1 (2%)  1 (1%) 1.0000 2 
Nalidixic acid  5 (23%) 9 (16%) 14 (18%) 0.5216 2 
Ciprofloxacin  0 (0%) 2 (4%) 2 (3%) 1.0000 2 
Chloramphenicol  2 (9%) 5 (9%) 7 (9%) 1.0000 2 
Gentamicin  0 (0%) 3 (5%) 3 (4%) 0.5547 2 
Amikacin  0 (0%) 1 (2%) 1 (1%) 1.0000 2 
Kanamycin  1 (5%) 5 (9%) 6 (8%) 0.6697 2 
Tetracycline  7 (32%) 20 (36%) 27 (35%) 0.7448 1 
Trimethoprim/sulfa-
methoxazole 
 6 (27%) 16 (29%) 22 (28%) 0.9087 1 
      
 
 
    
1: Chi-squared test      
 
2: Fisher's exact test      
 
bold: Statistically significant results    
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TABLE 2. Prevalence of virulence factor genes according to the clinical features. 201 
     





















hlyA 5 (23%) 28 (50%) 33 (42%) 0.02821  3.40 (1.10; 10.49) 0.0332  - - - 
cnf1 2 (9%) 19 (34%) 21 (27%) 0.02611  5.14 (1.08; 24.32) 0.0392  - - - 
sat1 9 (41%) 23 (41%) 32 (41%) 0.98951  1.01 (0.37; 2.74) 0.9895  - 
- - 
fimA 17 (77%) 50 (89%) 67 (86%) 0.27572  2.45 (0.66; 9.07) 0.1792  32.20 (1.28; 
809.78) 0.0349 
papA 8 (36%) 40 (71%) 48 (62%) 0.00421  4.37 (1.54; 12.43) 0.0056  - - - 
papC 11 (50%) 33 (59%) 44 (56%) 0.47421  1.43 (0.53; 3.86) 0.4752  - 
- - 
papEF 12 (55%) 38 (68%) 50 (64%) 0.27011  1.76 (0.64; 4.83) 0.2727  - 
- - 
papGI 0 (0%) 0 (0%) 0 (0%) -  1.00 - -  - 
- - 
papGII 8 (36%) 42 (75%) 50 (64%) 0.00141  5.25 (1.82; 15.13) 0.0021  - - - 
papGIII 9 (41%) 14 (25%) 23 (29%) 0.16561  0.48 (0.17; 1.37) 0.1697  - 
- - 
                                                       13
prs 15 (68%) 36 (64%) 51 (65%) 0.74481  0.84 (0.29; 2.40) 0.7450  - 
- - 
fyuA 4 (18%) 29 (52%) 33 (42%) 0.00691  4.83 (1.45; 16.10) 0.0103  - - - 
hra 8 (36%) 11 (20%) 19 (24%) 0.12161  0.43 (0.14; 1.27) 0.1270  0.13 (0.02; 0.96) 0.0452 
sfa 5 (23%) 18 (32%) 23 (29%) 0.41181  1.61 (0.51; 5.06) 0.4142  - 
- - 
ibeA 5 (23%) 9 (16%) 14 (18%) 0.52162  0.65 (0.19; 2.22) 0.4926  - 
- - 
iucC 14 (64%) 44 (79%) 58 (74%) 0.17401  2.10 (0.71; 6.16) 0.1787  53.38 (2.31; 
1233.37) 0.0130 
iutA 15 (68%) 10 (18%) 25 (32%) < 0.00011  0.10 (0.03; 0.31) 0.0001  0.01 (0.00; 0.13) 0.0016 
iha 4 (18%) 26 (46%) 30 (38%) 0.02101  3.90 (1.17; 13.00) 0.0267  20.61 (1.77; 240.12) 0.0157 
iroN 8 (36%) 36 (64%) 44 (56%) 0.02521  3.15 (1.13; 8.79) 0.0284  6.47 (1.30; 32.15) 0.0225 
ag43 10 (45%) 27 (48%) 37 (47%) 0.82611  1.12 (0.42; 3.01) 0.8262  - 
- - 
malX 9 (41%) 38 (68%) 47 (60%) 0.02861  3.05 (1.10; 8.44) 0.0319  - 
- - 
1: Chi-squared test            
2: Fisher's exact test            
3: Odds Ratio for present vs. absent           
bold: Statistically significant results           
 202 
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TABLE 1 E. coli isolates resistance profile according to the clinical features 1 








Ampicillin susceptible  9 (41%) 20 (36%) 29 (37%) 
0.6692 1 
resistant  13 (59%) 36 (64%) 48 (62%) 
Amoxicillin 
/clavulanic acid 
susceptible  19 (86%) 49 (88%) 68 (87%) 
1.0000 2 
resistant  3 (14%) 7 (12%) 10 (13%) 
Cefazolin susceptible  19 (86%) 42 (75%) 61 (78%) 
0.3680 2 
resistant  3 (14%) 14 (25%) 17 (22%) 
Cefuroxime susceptible  21 (95%) 54 (96%) 75 (96%) 
1.0000 2 
resistant  1 (5%) 2 (4%) 3 (4%) 
Cefoxitin susceptible  22 (100%) 55 (98%) 77 (99%) 
1.0000 2 
resistant  0 (0%) 1 (2%) 1 (1%) 
Cefotaxime susceptible  21 (95%) 55 (98%) 76 (97%) 
0.4872 2 
resistant  1 (5%) 1 (2%) 2 (3%) 
Ceftazidime susceptible  22 (100%) 56 (100%) 78 (100%) 
- 
resistant  0 (0%) 0 (0%) 0 (0%) 
Imipenem susceptible  22 (100%) 56 (100%) 78 (100%) 
- 
resistant  0 (0%) 0 (0%) 0 (0%) 
Piperacillin 
/tazobactam 
susceptible  22 (100%) 55 (98%) 77 (99%) 
1.0000 2 
resistant  0 (0%) 1 (2%)  1 (1%) 
Nalidixic acid susceptible  17 (77%) 47 (84%) 64 (82%) 
0.5216 2 
resistant  5 (23%) 9 (16%) 14 (18%) 
Ciprofloxacin susceptible  22 (100%) 54 (96%) 76 (97%) 
1.0000 2 
resistant  0 (0%) 2 (4%) 2 (3%) 
Chloramphenicol susceptible  20 (91%) 51 (91%) 71 (91%) 
1.0000 2 
resistant  2 (9%) 5 (9%) 7 (9%) 
Gentamicin susceptible  22 (100%) 53 (95%) 75 (96%) 
0.5547 2 
resistant  0 (0%) 3 (5%) 3 (4%) 
Amikacin susceptible  22 (100%) 55 (98%) 77 (99%) 
1.0000 2 
resistant  0 (0%) 1 (2%) 1 (1%) 
Kanamycin susceptible  21 (95%) 51 (91%) 72 (92%) 
0.6697 2 
resistant  1 (5%) 5 (9%) 6 (8%) 
Tetracycline susceptible  15 (68%) 36 (64%) 51 (65%) 
0.7448 1 
resistant  7 (32%) 20 (36%) 27 (35%) 
Trimethoprim/sulfa-
methoxazole 
susceptible  16 (73%) 40 (71%) 56 (72%) 
0.9087 1 
resistant  6 (27%) 16 (29%) 22 (28%) 
 
  
    
1: Chi-squared test       
2: Fisher's exact test       
 
     
 
bold: Statistically significant results    
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TABLE 2 Prevalence of virulence factor genes according to the clinical features 









(n=56) Total isolates p-value Odds Ratio3 
(95% Conf. 
Interval) p-value Odds Ratio3 (95% Conf. Interval) p-value 
Biofilm non-forming 10 (45%) 34 (61%) 44 (56%) 
0.22131 0.54 (0.20; 1.46) 0.2242 - - - 
forming 12 (55%) 22 (39%) 34 (44%) 
S. cerevisiae 
agglutination 
negative 6 (27%) 8 (14%) 14 (18%) 
0.20072 2.25 (0.68; 7.47) 0.1854 - - - 
positive 16 (73%) 48 (86%) 64 (82%) 
hlyA absent 17 (77%) 28 (50%) 45 (58%) 
0.02821 3.40 (1.10; 10.49) 0.0332 - - - 
present 5 (23%) 28 (50%) 33 (42%) 
cnf1 absent 20 (91%) 37 (66%) 57 (73%) 
0.02611 5.14 (1.08; 24.32) 0.0392 - - - 
present 2 (9%) 19 (34%) 21 (27%) 
sat1 absent 13 (59%) 33 (59%) 46 (59%) 
0.98951 1.01 (0.37; 2.74) 0.9895 - - - 
present 9 (41%) 23 (41%) 32 (41%) 
fimA absent 5 (23%) 6 (11%) 11 (14%) 
0.27572 2.45 (0.66; 9.07) 0.1792 32.20 (1.28; 809.78) 0.0349 
present 17 (77%) 50 (89%) 67 (86%) 
papA absent 14 (64%) 16 (29%) 30 (38%) 
0.00421 4.37 (1.54; 12.43) 0.0056 - - - 
present 8 (36%) 40 (71%) 48 (62%) 
papC absent 11 (50%) 23 (41%) 34 (44%) 
0.47421 1.43 (0.53; 3.86) 0.4752 - - - 
present 11 (50%) 33 (59%) 44 (56%) 
papEF absent 10 (45%) 18 (32%) 28 (36%) 
0.27011 1.76 (0.64; 4.83) 0.2727 - - - 
present 12 (55%) 38 (68%) 50 (64%) 
papGI absent 22 (100%) 56 (100%) 78 (100%) - 1.00 - - - - - 
papGII absent 14 (64%) 14 (25%) 28 (36%) 
0.00141 5.25 (1.82; 15.13) 0.0021 - - - 
present 8 (36%) 42 (75%) 50 (64%) 
papGIII absent 13 (59%) 42 (75%) 55 (71%) 
0.16561 0.48 (0.17; 1.37) 0.1697 - - - 
present 9 (41%) 14 (25%) 23 (29%) 
prs absent 7 (32%) 20 (36%) 27 (35%) 
0.74481 0.84 (0.29; 2.40) 0.7450 - - - 
present 15 (68%) 36 (64%) 51 (65%) 
fyuA absent 18 (82%) 27 (48%) 45 (58%) 0.00691 4.83 (1.45; 16.10) 0.0103 - - - 
present 4 (18%) 29 (52%) 33 (42%) 
hra absent 14 (64%) 45 (80%) 59 (76%) 
0.12161 0.43 (0.14; 1.27) 0.1270 0.13 (0.02; 0.96) 0.0452 
present 8 (36%) 11 (20%) 19 (24%) 
sfa absent 17 (77%) 38 (68%) 55 (71%) 
0.41181 1.61 (0.51; 5.06) 0.4142 - - - 
present 5 (23%) 18 (32%) 23 (29%) 
ibeA absent 17 (77%) 47 (84%) 64 (82%) 
0.52162 0.65 (0.19; 2.22) 0.4926 - - - 
present 5 (23%) 9 (16%) 14 (18%) 
iucC absent 8 (36%) 12 (21%) 20 (26%) 
0.17401 2.10 (0.71; 6.16) 0.1787 53.38 (2.31; 1233.37) 0.0130 
present 14 (64%) 44 (79%) 58 (74%) 
iutA absent 7 (32%) 46 (82%) 53 (68%) 
< 0.00011 0.10 (0.03; 0.31) 0.0001 0.01 (0.00; 0.13) 0.0016 
present 15 (68%) 10 (18%) 25 (32%) 
iha absent 18 (82%) 30 (54%) 48 (62%) 
0.02101 3.90 (1.17; 13.00) 0.0267 20.61 (1.77; 240.12) 0.0157 
present 4 (18%) 26 (46%) 30 (38%) 
iroN absent 14 (64%) 20 (36%) 34 (44%) 
0.02521 3.15 (1.13; 8.79) 0.0284 6.47 (1.30; 32.15) 0.0225 
present 8 (36%) 36 (64%) 44 (56%) 
ag43 absent 12 (55%) 29 (52%) 41 (53%) 
0.82611 1.12 (0.42; 3.01) 0.8262 - - - 
present 10 (45%) 27 (48%) 37 (47%) 
malX absent 13 (59%) 18 (32%) 31 (40%) 
0.02861 3.05 (1.10; 8.44) 0.0319 - - - 
present 9 (41%) 38 (68%) 47 (60%) 
            
1: Chi-squared test           
2: Fisher's exact test           
3: Odds Ratio for present vs. absent          
            
bold: Statistically significant results 
         
 
TABLE 3 Phylogenetic group distribution by clinical features 1 
  Clinical feature   
Phylogenetic group URS (n=32) GFS (n=24) NII (n=22) 
Total isolates 
(N=78) p-value 
Non B2 vs. B2  Non-B2 12 (38%) 5 (21%) 12 (55%) 29 (37%) 
0.0612 1 
B2 20 (62%) 19 (79%) 10 (45%) 49 (63%) 
A/B2/D  A 1 (3%) 2 (8%) 3 (14%) 6 (8%) 
0.0793 2 B2 20 (62%) 19 (79%) 10 (45%) 49 (63%) 
D 11 (34%) 3 (12%) 9 (41%) 23 (29%) 
 
      
1: Chi-squared test       
2: Fisher's exact test       
 
URS: UTI-related sepsis, GFS: Genital-focus sepsis, NII: Non-bacteraemic intra-amniotic infection  
 
bold: Statistically significant results     
 2 
 3 
